P-001. Real-world efficacy, safety and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience

INTRODUCTION: Clinical trials and real-world experiences evaluating ombitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination therapy have shown excellent rates of sustained virological response (SVR) and good safety profiles in patients with chronic hepatitis C v...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Turk J Gastroenterol
Hlavní autoři: Aygen, Bilgehan, Demirtürk, Neşe, Yıldız, Orhan, Çelen, Mustafa Kemal, Çelik, Ilhami, Barut, Şener, Ural, Onur, Batırel, Ayşe, Mıstık, Reşit, Şimşek, Funda, Asan, Ali, Ersöz, Gülden, Türker, Nesrin, Bilgin, Hüseyin, Hatipoğlu, Çiğdem Ataman, Karakeçili, Faruk
Médium: Artigo
Jazyk:Inglês
Vydáno: Turkish Society of Gastroenterology 2019
Témata:
AASLD - TASL CONNECT REGIONAL MEETING, March 15–16, 2019 - İstanbul, Turkey
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021020/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.07
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky